Equities

Akoya Biosciences Inc

AKYA:NSQ

Akoya Biosciences Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.19
  • Today's Change-0.03 / -0.93%
  • Shares traded94.53k
  • 1 Year change-20.45%
  • Beta1.3984
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8381113
Total Receivables, Net179.739.44
Total Inventory18149.01
Prepaid expenses3.796.769.28
Other current assets, total------
Total current assets122112141
Property, plant & equipment, net222510
Goodwill, net181818
Intangibles, net172021
Long term investments------
Note receivable - long term------
Other long term assets0.660.690.34
Total assets180176191
LIABILITIES
Accounts payable12119.44
Accrued expenses131812
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.770.620.27
Other current liabilities, total9.707.995.69
Total current liabilities353728
Total long term debt766433
Total debt776533
Deferred income tax0.040.090.03
Minority interest------
Other liabilities, total15169.18
Total liabilities12711770
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital284225217
Retained earnings (accumulated deficit)(230)(167)(96)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(0.01)--
Total equity5459121
Total liabilities & shareholders' equity180176191
Total common shares outstanding493837
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.